These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 25517304)

  • 1. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar.
    Zhu Z; Ramakrishnan B; Li J; Wang Y; Feng Y; Prabakaran P; Colantonio S; Dyba MA; Qasba PK; Dimitrov DS
    MAbs; 2014; 6(5):1190-200. PubMed ID: 25517304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
    Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
    Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.
    VanBrunt MP; Shanebeck K; Caldwell Z; Johnson J; Thompson P; Martin T; Dong H; Li G; Xu H; D'Hooge F; Masterson L; Bariola P; Tiberghien A; Ezeadi E; Williams DG; Hartley JA; Howard PW; Grabstein KH; Bowen MA; Marelli M
    Bioconjug Chem; 2015 Nov; 26(11):2249-60. PubMed ID: 26332743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
    Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
    J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.
    Axup JY; Bajjuri KM; Ritland M; Hutchins BM; Kim CH; Kazane SA; Halder R; Forsyth JS; Santidrian AF; Stafin K; Lu Y; Tran H; Seller AJ; Biroc SL; Szydlik A; Pinkstaff JK; Tian F; Sinha SC; Felding-Habermann B; Smider VV; Schultz PG
    Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16101-6. PubMed ID: 22988081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates.
    Zwaagstra JC; Sulea T; Baardsnes J; Radinovic S; Cepero-Donates Y; Robert A; O'Connor-McCourt MD; Tikhomirov IA; Jaramillo ML
    PLoS One; 2019; 14(12):e0226593. PubMed ID: 31891584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
    Singh AP; Sharma S; Shah DK
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.
    Ekholm FS; Pynnönen H; Vilkman A; Pitkänen V; Helin J; Saarinen J; Satomaa T
    ChemMedChem; 2016 Nov; 11(22):2501-2505. PubMed ID: 27786414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases.
    Qasba PK
    Bioconjug Chem; 2015 Nov; 26(11):2170-5. PubMed ID: 26065635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current ADC Linker Chemistry.
    Jain N; Smith SW; Ghone S; Tomczuk B
    Pharm Res; 2015 Nov; 32(11):3526-40. PubMed ID: 25759187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable and Potent Selenomab-Drug Conjugates.
    Li X; Nelson CG; Nair RR; Hazlehurst L; Moroni T; Martinez-Acedo P; Nanna AR; Hymel D; Burke TR; Rader C
    Cell Chem Biol; 2017 Apr; 24(4):433-442.e6. PubMed ID: 28330604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.